MNPR (Monopar Therapeutics) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $94.96
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Other Stockholders Equity?

Monopar Therapeutics MNPR +2.46% 35 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Monopar Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

Monopar Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Monopar Therapeutics's annual Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Monopar Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Other Stockholders Equity Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 -0.00 0.00 0.00

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Monopar Therapeutics (MNPR) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Other Stockholders Equity too high?
Monopar Therapeutics' current Other Stockholders Equity is $-0.00 Mil. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Other Stockholders Equity compare to MDXG and FTH?
Monopar Therapeutics' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Monopar Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$94.96
Price